Pharmacyclics Xcytrin Is "Not Approvable" For Brain Metastases
This article was originally published in Pharmaceutical Approvals Monthly
Pharmacyclics' anti-cancer product Xcytrin (motexafin gadolinium) received a "not approvable" letter, closing the current chapter in a year-long fight to get the drug approved
You may also be interested in...
Only three NDAs for new molecular entities have user fee goal dates in the remainder of 2007, which implies a marked slow-down in the pace of NME actions after FDA’s busy October.
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.